On May 30, 2024, Ascendis Pharma A/S held its Annual General Meeting, where shareholders voted on several key issues, including the approval of a €481.4 million loss to be carried forward and the election of new board members. A total of 50,141,674 shares, representing 86.11% of the votes, were cast, confirming management's report and various proposals with substantial support from shareholders.